| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
94,014,000 |
| Market
Cap: |
1.97(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.39 - $24.57 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s two primary product candidates are, SNDX-5613 and SNDX-6352 or axatilimab. Co. is developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1) protein for the treatment of MLL-rearranged acute leukemias and nucleophosmin 1 mutant acute myeloid leukemia, as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor. Co. has a collaboration and license agreement with Incyte Corporation for the development and commercialization of axatilimab.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
242,142 |
1,322,814 |
| Total Sell Value |
$0 |
$0 |
$4,873,574 |
$30,131,894 |
| Total People Sold |
0 |
0 |
3 |
8 |
| Total Sell Transactions |
0 |
0 |
5 |
37 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Podlesak Dennis |
|
– • – |
2022-09-15 |
4 |
AS |
$24.20 |
$1,617,381 |
D/D |
(66,840) |
75,763 |
|
15% |
|
| Podlesak Dennis |
|
– • – |
2022-09-15 |
4 |
OE |
$6.32 |
$422,429 |
D/D |
66,840 |
142,603 |
|
- |
|
| Morrison Briggs |
President, Head of R&D |
• • – |
2022-09-14 |
4 |
AS |
$23.80 |
$2,085,855 |
D/D |
(87,645) |
17,836 |
|
19% |
|
| Morrison Briggs |
President, Head of R&D |
• • – |
2022-09-14 |
4 |
OE |
$7.20 |
$631,044 |
D/D |
87,645 |
105,481 |
|
- |
|
| Ordentlich Peter |
Chief Scientific Officer |
• – – |
2022-08-24 |
4 |
AS |
$25.04 |
$625,893 |
D/D |
(25,000) |
265 |
|
-0% |
|
| Ordentlich Peter |
Chief Scientific Officer |
• – – |
2022-08-24 |
4 |
OE |
$6.32 |
$158,065 |
D/D |
25,000 |
2,419 |
|
- |
|
| Legault Pierre |
|
– • – |
2022-08-05 |
4 |
AS |
$23.02 |
$552,382 |
D/D |
(24,000) |
32,000 |
|
2% |
|
| Legault Pierre |
|
– • – |
2022-08-05 |
4 |
OE |
$8.93 |
$221,320 |
D/D |
24,000 |
46,000 |
|
- |
|
| Ordentlich Peter |
Chief Scientific Officer |
• – – |
2022-07-29 |
4 |
A |
$14.12 |
$3,742 |
D/D |
265 |
265 |
|
- |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2022-07-25 |
4 |
AS |
$21.06 |
$665,393 |
D/D |
(31,602) |
17,659 |
|
20% |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2022-07-25 |
4 |
OE |
$6.38 |
$201,621 |
D/D |
31,602 |
29,497 |
|
- |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2022-07-07 |
4 |
AS |
$21.00 |
$2,100 |
D/D |
(100) |
17,659 |
|
11% |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2022-07-07 |
4 |
OE |
$6.38 |
$638 |
D/D |
100 |
17,759 |
|
- |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2022-07-06 |
4 |
AS |
$21.07 |
$316,307 |
D/D |
(15,009) |
17,659 |
|
6% |
|
| Metzger Michael A |
Chief Executive Officer |
• • – |
2022-07-06 |
4 |
OE |
$6.38 |
$95,757 |
D/D |
15,009 |
32,668 |
|
- |
|
| Morrison Briggs |
President, Head of R&D |
• • – |
2022-07-01 |
4 |
AS |
$19.00 |
$1,183,430 |
D/D |
(62,292) |
17,836 |
|
23% |
|
| Morrison Briggs |
President, Head of R&D |
• • – |
2022-07-01 |
4 |
OE |
$7.20 |
$448,502 |
D/D |
62,292 |
80,128 |
|
- |
|
| Goldan Keith A. |
Chief Financial Officer |
• – – |
2022-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
3,205 |
3,205 |
|
- |
|
| Morrison Briggs |
President, Head of R&D |
• • – |
2022-04-04 |
4 |
AS |
$18.29 |
$57,220 |
D/D |
(3,128) |
17,836 |
|
26% |
|
| Morrison Briggs |
President, Head of R&D |
• • – |
2022-04-04 |
4 |
OE |
$10.90 |
$34,095 |
D/D |
3,128 |
20,964 |
|
- |
|
| Morrison Briggs |
President, Head of R&D |
• • – |
2022-04-01 |
4 |
AS |
$17.44 |
$1,763,515 |
D/D |
(101,045) |
17,836 |
|
34% |
|
| Morrison Briggs |
President, Head of R&D |
• • – |
2022-04-01 |
4 |
OE |
$10.90 |
$768,941 |
D/D |
70,545 |
88,381 |
|
- |
|
| Podlesak Dennis |
|
– • – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
75,763 |
|
- |
|
| Jarrett Jennifer |
|
– • – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
32,000 |
|
- |
|
| Legault Pierre |
|
– • – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
32,000 |
|
- |
|
208 Records found
|
|
Page 4 of 9 |
|
|
0.78 (3.59%) 
